2025-11-30 - Analysis Report
Okay, here's a comprehensive analysis of Transmedics Group Inc (TMDX) based on the provided data:

**1. Return Analysis:**

*   **TMDX Overview:** Transmedics Group Inc. is a medical technology company focused on developing and delivering innovative organ care system (OCS) technology for end-stage organ failure patients.
*   **TMDX Cumulative Return:** 263.32%
*   **VOO Cumulative Return (S&P 500):** 77.16%
*   **Divergence:** Current: 155.1, Relative Divergence: 71.4

**Analysis:** TMDX has significantly outperformed the S&P 500 (VOO) over the period analyzed. The current divergence is quite high (155.1), placing it in the upper range of historical divergence (71.4 relative divergence). This suggests strong outperformance relative to the market.

**Alpha, Beta Analysis:**

|            | CAGR     | MDD   | Alpha    | Beta   | Cap(B) |
|------------|----------|-------|----------|--------|--------|
| 2019-2021  | -18.0%   | 83.5% | -61.0%   | -0.0   | 0.7    |
| 2020-2022  | 94.0%    | 83.5% | 95.0%    | 0.0    | 2.1    |
| 2021-2023  | 65.0%    | 80.5% | 64.0%    | 0.1    | 2.7    |
| 2022-2024  | 130.0%   | 85.5% | 109.0%   | 0.1    | 2.1    |
| 2023-2025  | 184.0%   | 85.5% | 118.0%   | 0.3    | 5.0    |

**Analysis:**

*   **CAGR:**  The Compound Annual Growth Rate shows a dramatic improvement over the years, peaking in the most recent period. This indicates strong growth momentum.
*   **MDD:**  The Maximum Drawdown is consistently high, indicating significant volatility and risk.
*   **Alpha:**  The Alpha is very high and positive in most periods, demonstrating that TMDX has consistently outperformed its expected return based on its beta.
*   **Beta:** The Beta is low, indicating that TMDX's price is not very sensitive to market movements. It has very weak coorelation to the overall market.
*   **Cap(B):** Market cap is rising, indicating market confidence to the stock.

**2. Recent Stock Price Fluctuations:**

*   **Current Close:** 146.31
*   **Previous Close:** 145.75, **Change:** 0.38
*   **5-day SMA:** 141.84
*   **20-day SMA:** 127.1655
*   **60-day SMA:** 120.7348

**Analysis:** The stock price is trading above its 5-day, 20-day, and 60-day SMAs, indicating an upward trend. The short-term (5-day) SMA is closest to the current price, followed by the 20-day, then the 60-day, confirming the recent upward momentum. The small change in price of $0.38, despite some news in the headlines, is suggesting that the market does not see a large significance in the price changes from the recent news.

**3. Indicator Analysis:**

*   **Market Risk Indicator (MRI):** 0.9 (High Investment Recommended)
*   **RSI:** 70.90 (Approaching overbought territory, but not yet extreme)
*   **PPO:** 2.11 (Positive, indicating an upward trend)
*   **Hybrid Signal:** Cash_0%_Buy 100% of cash (8 shares - Very Safe - MRI:0.90)
*   **Recent (20 days) relative divergence change:** 13.5 (+): Short-term increase
*   **Expected Return (%):** 38.9 (High expected return compared to S&P 500)

**Analysis:**

*   The MRI suggests a relatively high degree of investment safeness.
*   The RSI suggests the stock is near the upper limit of being overbought.
*   The positive PPO confirms the uptrend.
*   The hybrid signal recommends a full investment, aligned with the high MRI score.
*   The increase in relative divergence highlights recent outperformance.
*   The high expected return is a positive sign for long-term investors.

**4. Recent News & Significant Events:**

*   **Q3 Earnings Beat:** TMDX beat Q3 earnings estimates, but the stock still fell initially. This suggests that the positive results may have already been priced into the stock.
*   **Executive Stock Sale:** An executive sold shares of TMDX, which could be perceived negatively by some investors.
*   **Stock Surge:** TMDX stock experienced a 13% surge on a particular day.
*   **FDA Approvals:** The company has received FDA approvals, likely contributing to positive sentiment.
*   **Analyst Commentary:** Seeking Alpha noted that Q3 results disappointed, as expected, but issued a rating upgrade.

**4-2. Analyst Opinions:**

*   **Consensus:** Buy (Mean: 1.67)
*   **Opinions:** 11
*   **Target Price:** Average: 141.91, High: 170.00, Low: 114.00

**Analysis:** Analyst sentiment is generally positive, with a consensus rating of "Buy."  The average target price (141.91) is slightly *below* the current price (146.31), suggesting limited immediate upside potential based on current analyst estimates. However, the high target price (170.00) offers a more bullish long-term view.

**5. Comprehensive Analysis Summary:**

TMDX has shown strong outperformance relative to the S&P 500, driven by its innovative organ care system technology and recent FDA approvals. Financial metrics, like CAGR and Alpha, are trending positively. The recent stock price movement reflects this bullish sentiment, trading above its moving averages.

While the RSI indicates the stock is approaching overbought territory, and the MRI suggests a relatively safe investment with a high expected return.

The news headlines are mixed. While Q3 earnings beat estimates and FDA approvals are positives, an executive stock sale could raise concerns. Analyst sentiment is predominantly positive, but the average target price is slightly below the current price.

**Overall Recommendation:**

Based on the data, TMDX appears to be a promising investment for those seeking growth potential. However, investors should be aware of the high MDD, indicating volatility. Keep a close eye on the stock's RSI value. Furthermore, the stock's average target price being lower than the current price could imply that the stock's market value has surpassed its' intrinsic value based on current metrics. The executive selling shares and analyst commentary should be monitored closely.

**Important Disclaimer:** This is a summary and analysis based solely on the provided data. It is not financial advice. Consider consulting with a qualified financial advisor before making any investment decisions.


**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.